semaglutide microspheres (GB-7001) / G2GBIO - LARVOL DELTA

Effect of hydroxyethyl starch on drug stability and release of semaglutide in PLGA microspheres. (PubMed, Int J Pharm) - "Additionally, the optimized semaglutide microspheres provided nearly three weeks of glycemic control with adequate safety. In conclusion, adding HES to the internal aqueous phase improved the in-situ drug stability and release behavior of semaglutide-loaded PLGA microspheres, effectively increasing the peptide drug payload in PLGA microspheres."

Journal

PK Studies in Rats and Minipigs of GB-7001, a Novel Monthly Microsphere Formulation Containing High Drug Content of Semaglutide (ADA 2023) - "Currently, the longest-acting GLP-1 product (including dulaglutide, semaglutide, and tirzepatide) is a weekly injection, and there are no approved once-monthly long-acting injectables...Although the release rate of GB-7001 slows after 28 days, semaglutide was detected within the quantifiable range for up to 56 days.In conclusion, GB-7001 is an improved 1-month semaglutide injectable that has shown promising results in PK studies in rats and minipigs. Further preclinical studies of the final formulation are scheduled, and GB-7001 is planned to apply for IND once the final formulation is selected."

Late-breaking abstract • Preclinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus